Senate Hearing on mRNA-Cancer Link Adds Risk for Vaccine Sector

A Senate hearing Wednesday in Washington examined whether mRNA COVID-19 vaccines can cause cancer. The session, called 'Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications and Research,' was led by Wisconsin Sen. Ron Johnson.

The central testimony came from Dr. Angus Dalgleish, professor emeritus of oncology at the University of London. Dalgleish told lawmakers that six of his melanoma patients, stable for years, relapsed after receiving mRNA vaccines. He offered no published data to support the pattern. He said the pattern warranted investigation.

The hearing also included witnesses who alleged that federal health agencies suppressed vaccine safety research and interfered with independent studies. The recording did not detail their full testimony. Johnson has not announced a follow-up session or specific legislation.

Vaccine manufacturers already face litigation over alleged side effects. Pfizer and Moderna have defended their products in multiple lawsuits. The hearing adds to a public record that plaintiffs may cite.

For investors tracking the stock market analysis, the hearing marks a risk event because it provides a platform for claims that could resurface in later proceedings. A sustained drop in vaccine confidence has historically hurt prescription volumes and revenue projections for vaccine developers. No immediate policy change is expected.

What would make the risk worse: more patient reports from physicians, a federal agency acknowledging data gaps, or bipartisan calls for a formal investigation. What could reduce it: controlled studies that fail to replicate the pattern Dalgleish described, or the absence of further hearings.

The hearing lasted about three hours. No markup or bill has been introduced as of Thursday.